Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias
about
Short and tall stature: a new paradigm emergesA pathway to bone: signaling molecules and transcription factors involved in chondrocyte development and maturationAdvances in Skeletal Dysplasia GeneticsMeclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasiaA novel loss-of-function mutation in Npr2 clarifies primary role in female reproduction and reveals a potential therapy for acromesomelic dysplasia, Maroteaux typeEvaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasiaThe Fibroblast Growth Factor signaling pathwayThe indolocarbazole, Gö6976, inhibits guanylyl cyclase-A and -B.A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B.Amino-terminal propeptide of C-type natriuretic peptide (NTproCNP) predicts height velocity in healthy children.FGFR3/fibroblast growth factor receptor 3 inhibits autophagy through decreasing the ATG12-ATG5 conjugate, leading to the delay of cartilage development in achondroplasiaRegulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.Skeletal Dysplasias: Growing Therapy for Growing Bones.FGFR3 targeting strategies for achondroplasia.Height matters-from monogenic disorders to normal variation.Advances in treatment of achondroplasia and osteoarthritis.Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia.Molecular Physiology of Membrane Guanylyl Cyclase Receptors.Short Anabolic Peptides for Bone Growth.Current Care and Investigational Therapies in Achondroplasia.Achondroplasia: Development, pathogenesis, and therapy.Mouse models for the study of cranial base growth and anomalies.Overexpression of C-type Natriuretic Peptide in Endothelial Cells Protects against Insulin Resistance and Inflammation during Diet-induced ObesityMolecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia.Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.Adipocyte-specific expression of C-type natriuretic peptide suppresses lipid metabolism and adipocyte hypertrophy in adipose tissues in mice fed high-fat diet.Dephosphorylation of the NPR2 guanylyl cyclase contributes to inhibition of bone growth by fibroblast growth factor.HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.Circulatory CNP Rescues Craniofacial Hypoplasia in Achondroplasia.Rats deficient C-type natriuretic peptide suffer from impaired skeletal growth without early death.Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.Acromesomelic dysplasia, type maroteaux caused by novel loss-of-function mutations of the NPR2 gene: Three case reports.Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.C-type natriuretic peptide analog treatment of craniosynostosis in a Crouzon syndrome mouse modelInhibiting the integrated stress response pathway prevents aberrant chondrocyte differentiation thereby alleviating chondrodysplasiaExogenous C-type natriuretic peptide restores normal growth and prevents early growth plate closure in its deficient rats
P2860
Q26781983-2457A739-2711-4833-A57F-10AF7FABA13BQ26995910-9697708F-A8D5-4D85-9620-46C489D0A9AFQ28261525-51554CFE-E0E2-4FC3-94D9-C992098D7D9CQ28535920-C735953D-F498-4256-8000-94690CE327B2Q30359787-A6C7C439-01EA-4F2A-9E62-C55E064DC36CQ34314761-319988BD-BE35-4FFB-AB79-46F98CCB2F51Q34467171-912FBC20-2F20-4A33-BCF4-564D3B94D253Q35287220-4BD4F499-0102-4B80-800A-949ACB3F42D1Q35548309-8D91A47D-4104-4540-84B5-7CAD0B6D6E14Q36304869-C40D1280-6BBE-4370-BF7D-CAD47D9A4FF9Q36777218-3A42106A-FBBC-4C67-A93E-6CCE54D9F0A4Q36867743-0151393A-1246-4CE6-99F8-3274FD743BC2Q37681118-DD1DC5D0-66C5-4F1D-9EEB-E2F4474424FFQ38007566-F803CA33-B5CC-423F-B77F-20530F7B0F1EQ38075771-8E119CDA-BDFB-4DEC-B32E-9B6A146B9C52Q38601075-4A294865-ECAF-40B4-9D86-8B07FD236703Q38645745-B7C30A8C-70C2-4175-A09B-E48CAF5EA42DQ38794203-309657F8-2090-49C8-B244-AD2053B7561BQ38864194-2E39DF4E-B698-4630-866F-044003FA77FCQ38948779-45F0F8E2-3E3D-48E6-A590-7A438725292FQ39041957-6B9242F6-EB5A-41AE-9A79-AF75E66BF538Q39393785-F5B14D3D-62B0-4050-9AC6-24DBEE27300FQ41547951-A63F08F1-1614-41D0-A169-4604598E8B48Q47612372-37955A43-A3A4-4CF4-9563-6F9D0CB2D1DDQ47855200-3BC1C41B-1926-4476-BA79-C15F61739252Q48042234-214E9C1A-583D-4200-92F8-0C3483373157Q48188760-AA3A061E-C6D5-433B-BE88-2CABD3564918Q50493259-FD1E5D1F-53AD-4B7C-94B6-D8FD4C77F297Q51840632-4F3C90C9-F104-4D23-AAB3-95C5FCD2AE9DQ52642700-A6B02F3A-071A-4FB1-A249-A7439CEB6C00Q52826459-1ADDEB81-4106-4AE3-AE6D-7C7008C87A79Q52902805-77A63E3A-F919-4468-8D7E-26C4B48E1CBCQ54408207-AFC9689F-55FE-4D5B-91E0-89DDA119B493Q56261671-6FEDCC26-166F-4577-A949-EAB329EB67A1Q56533422-91B7233C-3D14-4BF0-894B-CFAE6A36588EQ58713276-721ABA52-153F-45CC-BB82-F6EBA5922944
P2860
Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systemic administration of C-t ...... rategy for skeletal dysplasias
@en
Systemic administration of C-t ...... ategy for skeletal dysplasias.
@nl
type
label
Systemic administration of C-t ...... rategy for skeletal dysplasias
@en
Systemic administration of C-t ...... ategy for skeletal dysplasias.
@nl
prefLabel
Systemic administration of C-t ...... rategy for skeletal dysplasias
@en
Systemic administration of C-t ...... ategy for skeletal dysplasias.
@nl
P2093
P2860
P356
P1433
P1476
Systemic administration of C-t ...... rategy for skeletal dysplasias
@en
P2093
Akihiro Yasoda
Hidetomo Kitamura
Hiroshi Arai
Kazuwa Nakao
Masako Miura
Naoaki Murao
Naotetsu Kanamoto
Toshihito Fujii
Yasato Komatsu
P2860
P304
P356
10.1210/EN.2008-1676
P407
P577
2009-03-12T00:00:00Z